Works matching AU Joohyuk Sohn


Results: 58
    1
    2

    Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.

    Published in:
    Oncologist, 2025, v. 30, n. 5, p. 1, doi. 10.1093/oncolo/oyaf048
    By:
    • Ueno, Naoto T;
    • Cottone, Francesco;
    • Dunton, Kyle;
    • Jacot, William;
    • Yamashita, Toshinari;
    • Sohn, Joohyuk;
    • Tokunaga, Eriko;
    • Prat, Aleix;
    • Tsurutani, Junji;
    • Park, Yeon Hee;
    • Rugo, Hope S;
    • Xu, Binghe;
    • Cardoso, Fatima;
    • Mitri, Zahi;
    • Mahtani, Reshma;
    • Aguilar, Cecilia Orbegoso;
    • Xiao, Feng;
    • Harbeck, Nadia;
    • Cameron, David A;
    • Modi, Shanu
    Publication type:
    Article
    3
    4

    Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study.

    Published in:
    Breast Cancer Research, 2025, v. 27, n. 1, p. 1, doi. 10.1186/s13058-024-01946-y
    By:
    • Dent, Rebecca;
    • Cortés, Javier;
    • Park, Yeon Hee;
    • Muñoz-Couselo, Eva;
    • Kim, Sung-Bae;
    • Sohn, Joohyuk;
    • Im, Seock-Ah;
    • Holgado, Esther;
    • Foukakis, Theodoros;
    • Kümmel, Sherko;
    • Yearley, Jennifer;
    • Wang, Anran;
    • Nebozhyn, Michael;
    • Huang, Lingkang;
    • Cristescu, Razvan;
    • Jelinic, Petar;
    • Karantza, Vassiliki;
    • Schmid, Peter
    Publication type:
    Article
    5
    6

    Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.

    Published in:
    Cancer Immunology, Immunotherapy, 2024, v. 73, n. 10, p. 1, doi. 10.1007/s00262-024-03782-7
    By:
    • Park, Changhee;
    • Suh, Koung Jin;
    • Kim, Se Hyun;
    • Lee, Kyung-Hun;
    • Im, Seock-Ah;
    • Kim, Min Hwan;
    • Sohn, Joohyuk;
    • Jeong, Jae Ho;
    • Jung, Kyung Hae;
    • Lee, Kyoung Eun;
    • Park, Yeon Hee;
    • Kim, Hee-Jun;
    • Cho, Eun Kyung;
    • Choi, In Sil;
    • Noh, Seung-Jae;
    • Shin, Inkyung;
    • Cho, Dae-Yeon;
    • Kim, Jee Hyun
    Publication type:
    Article
    7
    8

    On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates.

    Published in:
    Breast Cancer Research, 2023, v. 25, n. 1, p. 1, doi. 10.1186/s13058-022-01601-4
    By:
    • Kim, Chang Gon;
    • Kim, Min Hwan;
    • Kim, Jee Hung;
    • Kim, Seul-Gi;
    • Kim, Gun Min;
    • Kim, Tae Yeong;
    • Ryu, Won-Ji;
    • Kim, Jee Ye;
    • Park, Hyung Seok;
    • Park, Seho;
    • Cho, Young Up;
    • Park, Byeong Woo;
    • Kim, Seung Il;
    • Jeong, Joon;
    • Sohn, Joohyuk
    Publication type:
    Article
    9
    10
    11
    12

    Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer.

    Published in:
    JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 9, p. 1036, doi. 10.1093/jnci/djad080
    By:
    • Kim, Min Hwan;
    • Kim, Gun Min;
    • Ahn, Jin Mo;
    • Ryu, Won-Ji;
    • Kim, Seul-Gi;
    • Kim, Jee Hung;
    • Kim, Tae Yeong;
    • Han, Hyun Ju;
    • Kim, Jee Ye;
    • Park, Hyung Seok;
    • Park, Seho;
    • Park, Byeong Woo;
    • Kim, Seung Il;
    • Jeong, Joon;
    • Lee, Jieun;
    • Paik, Soonmyung;
    • Kim, Sangwoo;
    • Jung, Kyung Hae;
    • Cho, Eun Hae;
    • Sohn, Joohyuk
    Publication type:
    Article
    13
    14
    15
    16

    A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer.

    Published in:
    NPJ Breast Cancer, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41523-024-00684-w
    By:
    • Noguchi, Emi;
    • Yamanaka, Takashi;
    • Mukai, Hirofumi;
    • Yamamoto, Naohito;
    • Chung, Chi-Feng;
    • Lu, Yen-Shen;
    • Chang, Dwan-Ying;
    • Sohn, Joohyuk;
    • Kim, Gun Min;
    • Lee, Kyung-Hun;
    • Lee, Soo-Chin;
    • Iwasa, Tsutomu;
    • Iwata, Hiroji;
    • Watanabe, Kenichi;
    • Jung, Kyung Hae;
    • Tanabe, Yuko;
    • Kang, Seok Yun;
    • Yasojima, Hiroyuki;
    • Aogi, Kenjiro;
    • Tokunaga, Eriko
    Publication type:
    Article
    17

    A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15).

    Published in:
    Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359231225029
    By:
    • Baek, Sun Kyung;
    • Jeong, Jae-ho;
    • Jung, KyungHae;
    • Ahn, Hee Kyung;
    • Kim, Min Hwan;
    • Sohn, Joohyuk;
    • Park, In Hae;
    • Ahn, Jin Seok;
    • Lee, Dae-Won;
    • Im, Seock-Ah;
    • Sim, Sung Hoon;
    • Lee, Keun Seok;
    • Hyun Kim, Jee;
    • Shim, Hyun-Jeong;
    • Chae, Yeesoo;
    • Koh, Su-Jin;
    • Lee, Hyorak;
    • Lee, Jieun;
    • Byun, Jae-Ho;
    • Seol, Youngmi
    Publication type:
    Article
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29

    Molecular alterations and poziotinib efficacy, a pan‐HER inhibitor, in human epidermal growth factor receptor 2 (HER2)‐positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2‐positive breast cancer patients

    Published in:
    International Journal of Cancer, 2019, v. 145, n. 6, p. 1669, doi. 10.1002/ijc.32188
    By:
    • Kim, Ji‐Yeon;
    • Lee, Eunjin;
    • Park, Kyunghee;
    • Jung, Hae Hyun;
    • Park, Woong‐Yang;
    • Lee, Kyung‐Hun;
    • Sohn, Joohyuk;
    • Lee, Keun Seok;
    • Jung, Kyung Hae;
    • Kim, Jee Hyun;
    • Lee, Ki Hyeong;
    • Im, Seock‐Ah;
    • Park, Yeon Hee
    Publication type:
    Article
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47

    Genomic landscape of extraordinary responses in metastatic breast cancer.

    Published in:
    Communications Biology, 2021, v. 4, n. 1, p. 1, doi. 10.1038/s42003-021-01973-x
    By:
    • Lim, Sun Min;
    • Kim, Eunyoung;
    • Jung, Kyung Hae;
    • Kim, Sora;
    • Koo, Ja Seung;
    • Kim, Seung Il;
    • Park, Seho;
    • Park, Hyung Seok;
    • Park, Byoung Woo;
    • Cho, Young Up;
    • Kim, Ji Ye;
    • Paik, Soonmyung;
    • Kwon, Nak-Jung;
    • Kim, Gun Min;
    • Kim, Ji Hyoung;
    • Kim, Min Hwan;
    • Jeon, Min Kyung;
    • Kim, Sangwoo;
    • Sohn, Joohyuk
    Publication type:
    Article
    48
    49
    50

    A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy.

    Published in:
    Cancer Research & Treatment, 2023, v. 55, n. 4, p. 1096, doi. 10.4143/crt.2022.1565
    By:
    • Young-Woong Won;
    • Jin-Hyoung Kang;
    • Jung Hye Kwon;
    • Dong-Hoe Koo;
    • Jung Hun Kang;
    • Chi Hoon Maeng;
    • Hee Kyung Ahn;
    • Sung Yong Oh;
    • Dae-Won Lee;
    • Joohyuk Sohn;
    • So Yeon Oh;
    • Kyung Hee Lee;
    • Su-Jin Koh;
    • Keun Seok Lee;
    • Chan-Kyu Kim;
    • Ji-Yeon Kim;
    • Jun Ho Ji;
    • Sung-Bae Kim;
    • Joo Young Ha;
    • Ho Young Kim
    Publication type:
    Article